Boehringer Ingelheim mini oral: A snapshot of GDMT use among Australian primary care patients with heart failure – how do we move the needle?
Friday, August 15, 2025 |
10:15 AM - 10:45 AM |
Theatrette 2 |
Details
A/Prof. Nelson will present on data from CHEERS RWE study (focusing on HFrEF) as well as practical implications from STRONG HF to create robust models for HFrEF.
Speaker
Prof Andrew Coats
Cardiologist
Heart Research Institute
A snapshot of GDMT use among Australian primary care patients with heart failure – how do we move the needle?
10:15 AM - 10:45 AMBiography
Professor Coats is an experienced academic leader and entrepreneur with three decades of international experience in four of the world’s top universities. He has over 850 peer-reviewed papers, over 175,000 career citations and an H-Index of 168. He has been named one of the top 1,000 researchers of all time by the Webometrics Ranking of World Universities, and author of more than 20 awarded patents. He has launched two successful spin-out biotechnology companies with capital raises in excess of USD100M and licensing deals of more than USD1Billion. Professor Coats is a fully accredited physician and cardiologist in the UK and Australia, a qualified company director, and a trained and experienced fundraiser. He holds two higher doctorates (DSc, Imperial; DM, Oxon) for separate research areas and has held senior offices in five major Professional Societies, and served as President of the largest specialist society in his field (the Heart Failure Association).
Assoc Prof Adam Nelson
Interventional Cardiologist
Royal Adelaide and Queen Elizabeth Hospitals / University of Adelaide
A snapshot of GDMT use among Australian primary care patients with heart failure – how do we move the needle?
10:15 AM - 10:45 AMBiography
Adam Nelson MBBS MBA/MPH PhD FRACP is an early career interventional cardiologist and clinical trialist appointed at the Royal Adelaide and Queen Elizabeth Hospitals, and clinical academic at the University of Adelaide. He is a clinical lead of national and international trials evaluating emerging cardiometabolic therapies and vaccines.
